2,217 press releases in English indexed under biotech & pharma.
DOWNERS GROVE, Ill., Oct. 20, 2026 -- Systech, part of Markem-Imaje and Dover and a leading provider of pharmaceutical serialization and traceability solutions, today announced the launch of two new integrated packaging solutions designed to help pharmaceutical manufacturers...
THOUSAND OAKS, Calif., Oct. 20, 2026 -- Amgen (NASDAQ:AMGN) will host a webcast call for the investment community in conjunction with the European Society of Medical Oncology Congress (ESMO) 2026 on Saturday, October 24, 2026 at 11:30 a.m. PT. Murdo Gordon, executive vice...
Deputy Speaker Thomas Tayebwa has said the Bachelor of Pharmacy programme at Mbarara University of Science and Technology (MUST) remains accredited by the National Council for Higher Education (NCHE) for the next four years despite a dispute over its professional recognition by the Pharmaceutical Society of Uganda (PSU). Tayebwa made the remarks during the plenary sitting on Tuesday, 20 October 2026 following concerns over the PSU’s reported withdrawal of the professional recognition of the programme. Tayebwa revealed that he contacted the NCHE Executive Director, who confirmed that the programme remains accredited. “The students are learning and being taught an accredited course,” Tayebwa told Parliament. He added that NCHE accredited the programme in consultation with relevant stakeholders including the Pharmaceutical Society. The Deputy Speaker said there is an overlap in the mandates of the Pharmaceutical Society and the National Council for Higher Education under the laws governing pharmacy training. He directed the Minister for Education and Sports to present a comprehensive statement to Parliament on Thursday, 22 October 2026. He also asked the minister to consult the Attorney General and directed the Attorney General to present the legal framework governing the matter. The Leader of the Opposition, Hon. Joel Ssenyonyi said the concerns raised by PSU appear to extend beyond programme recognition to the qualifications of the person heading Mbarara University Department of Pharmacy. Ssenyonyi said a letter from the professional body questioned whether the department was headed by someone with the qualifications required for the position. He urged the government and relevant authorities to address the concerns promptly to prevent further uncertainty among students and graduates. “If it is a question of somebody heading a department who requires a particular set of qualifications, I think that should be sorted out so that students are not in disarray,” Ssenyonyi said. Distributed by APO Group on behalf of Parliament of the Republic of Uganda.
Poster 0122 on Sunday, November 8: CD206-targeted dexamethasone prodrug was superior to systemic dexamethasone in a 309-patient randomized trial (HR 2.31; p<0.0001), with no systemic steroid added in the '005 arm; abstract positions ' 005 as a potential steroid-sparing adjunct to biologic therapy, including in PMR, sJIA,
LOS ANGELES, CA - October 20, 2026 - Quantum BioPharma (NASDAQ: QNTM) was featured in a Men’s Fitness article by Lakshan Weeraratne examining clinical trial results for Unbuzzd, an alcohol recovery formulation developed by Quantum and licensed to Unbuzzd Wellness. The article highlights findings from a company-sponsored, placebo-controlled study involving 26 healthy adults, with 24 completing both treatment sessions. Researchers reported significantly lower estimated blood alcohol concentrations at several time points, improved self-rated alertness and reduced headache severity on certain assessments. Among 17 participants identified as rapid responders, the average percentage decline in estimated blood alcohol during the first 30 minutes was 40.7% greater with Unbuzzd than with placebo. The Men’s Fitness article also emphasized the study’s limitations, including its small sample size, company sponsorship and mixed results across broader measures of hangover severity and cognitive impairment. While the findings suggest potential benefits for certain alcohol recovery measures, the article noted that larger, independent clinical trials are needed to confirm the results. It also cautioned that increased alertness does not indicate sobriety or fitness to drive. About Quantum BioPharma Ltd. Quantum is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. (“Lucid”), Quantum is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. Quantum invented UNBUZZD(TM) and spun out its OTC version to a company, Unbuzzd Wellness Inc. (“Unbuzzd”) (formerly, Celly Nutrition Corp.), led by industry veterans. Quantum retains ownership of 19.84% (as of March 31, 2026) of Unbuzzd at www.unbuzzd.com. The agreement with Unbuzzd also includes royalty payments of 7% of sales from unbuzzd(TM) until payments to Quantum total $250 million. Once $250 million is reached, the royalty drops to 3% in perpetuity. Quantum retains 100% of the rights to develop similar products or alternative formulations specifically for pharmaceutical and medical uses. Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: https://IBN.ai/Disclaimer The latest news and updates relating to QNTM are available in the company’s newsroom at https://ibn.fm/QNTM Forward Looking Statements Certain statements in this article are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties, and other factors that may cause actual results to differ materially from the information expressed or implied by these forward-looking statements and may not be indicative of future results. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management's control, including the risks set forth under the heading "Risk Factors" discussed under the caption "Item 1A. Risk Factors" in Part I of the Company's most recent Annual Report on Form 10-K or any updates discussed under the caption "Item 1A. Risk Factors" in Part II of the Company's Quarterly Reports on Form 10-Q and in the Company's other filings with the SEC. Undue reliance should not be placed on the forward-looking statements in this article in making an investment decision, which are based on information available to us on the date hereof. All parties undertake no duty to update this information unless required by law.
Approval based on phase III data showing unprecedented functional cure rates compared to standard of care
New research highlights growing optimism for disease-modifying therapies, even as physicians weigh the transformative potential of cell therapy against safety and practical considerations; Novartis' ianalumab emerges as a leading non-cell therapy contender. New research highlights growing optimism for disease-modifying therapies, even as physicians weigh the transformative potential of cell therapy against safety and practical considerations; Novartis' ianalumab emerges as a leading non-cell therapy contender.
President Donald J. Trump returns to North Carolina today with a clear record of results that put Tar Heel families, workers, seniors, and communities first. Since taking office, the Trump Administration has driven down crime, returned money to workers’ and seniors’ pockets, and unleashed a surge of advanced manufacturing, pharmaceutical, aerospace, biotechnology, and SI investment […] The post Delivering for North Carolina: Safer Streets, Bigger Paychecks, and a Manufacturing Boom Under President Trump appeared first on The White House.
FORT MYERS, Fla., Oct. 20, 2026 -- Insurer-driven step-editing practices in oncology continue to increase the risk of serious harm to cancer patients and providers, according to an extensive review conducted by physician and executive leaders of Florida Cancer Specialists &...
Key Highlights Record revenue: preliminary nine-month 2026 revenue of approximately $54.3 million, up 19%, with every quarter of 2026 setting a record 2026 outlook reaffirmed: full-year revenue expected to surpass $90 million, up approximately 38%, the largest single-year revenue increase in the Company's history Record fourth quarter expected: revenue of approximately $35.7 million or more, up approximately 81% from the fourth quarter of 2025 Multiple engines of growth: pharmaceutical contract manufacturing and distribution, proprietary brands and U.S. e-commerce all expected to contribute U.S. e-commerce scaling rapidly: 8,940 active U.S. subscriptions as of October 19, 2026, up 42% in five days, with approximately $15 million in revenue and $10.5 million in gross profit expected in the fourth quarter Record CMO pipeline: more than 32.7 million units at Cana Laboratories, up sixfold since mid-2024 Record distribution volumes: CosmoFarm serving more than 1,500 pharmacies, with revenue up approximately 4.3 times under Cosmos Health ownership Global brand expansion: proprietary brands sold in more than 40 countries, with particular momentum in Europe and the Gulf Diversified balance sheet: approximately $20 million in non-core assets, including real estate and digital assets, and total liabilities down 13.3% in the first half of 2026 Share repurchases: more than 5.1 million shares repurchased for approximately $1.1 million R&D in weight management: advancing CCX0722, a hydrogel-based weight-management device with patent applications in four major markets Path to 2029: <
Biopharmaceuticals lead demand as firms invest in cold storage, IoT-enabled monitoring, predictive analytics and reusable thermal packaging to improve compliance, efficiency and shipment integrity. Biopharmaceuticals lead demand as firms invest in cold storage, IoT-enabled monitoring, predictive analytics and reusable thermal packaging to improve compliance, efficiency and shipment integrity.
Partnership unites the ReBalU Protocol, Vivos's sleep platform, and a new test for cells primed for chronic disease, reaching nearly 500,000 chronic‑disease patients